Marcella Sessa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marcella Sessa has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Claudio Napoli
Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy
3 shared publications - Fabio Didonè
Evaluative Epidemiology Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale Dei Tumori, 20133 Milan, Italy
3 shared publications - Fabio Savoia
Childhood Cancer Registry of Campania, Santobono-Pausilipon Children’s Hospital, 80129 Naples, Italy
3 shared publications - Laura Botta
Epidemiology and Prevention Unit Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
3 shared publications - Massimo Conte
Clinical Oncology Unit, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy
3 shared publications - Riccardo Capocaccia
Editorial board, Epidemiologia e Prevenzione, Milan, Italy
3 shared publications
Latest Publications
- Open Access
Toronto Staging Guidelines for Wilms Tumour: The Meeting Point Between Clinicians and Epidemiologists—Results of the BENCHISTA-ITA Project
Background/Objectives: Despite overall excellent outcomes for Wilms tumour, regional variations in stage at diagnosis and care pathways remain a concern across Europe. We evaluated stage distribution, three-year survival, and treatment patterns in Italy, considering hospital care as a proxy for healthcare capacity and migration. Methods: Data were obtained from 26 population-based cancer registries (PBCRs), covering 148 patients (ages 0–14) diagnosed between 2013 and 2017, representing about 80% of the Italian population. Stage was classified according to the Toronto guidelines. Information on treatment and diagnosed/treating hospitals was collected. Stage at diagnosis was further refined using probabilistic linkage with the clinical registry 1.01 Model. Overall survival, defined as all-cause mortality, was estimated using the Kaplan–Meier method. Results: Most patients presented with localized disease (77%), 32% Stage I, while 19% were Stage IV. Three-year survival analysis showed significant differences between stages, ranging from 98% in patients with Stage I to 78% in the ones with Stage IV. No significant disparity across the Italian regions was observed in stage distribution or survival. Diagnoses and treatments were mostly (>90%) centralized in the same region for patients residing in the Centre or North of Italy. However, the cross-regional health migration from the South was of about 30% for diagnosis and larger for treatments. Conclusions: This study shows that standardized staging improves data comparability and highlights challenges in managing metastatic cases and regional care pathways. The results support the use of clinical and PBCR information to interpret survival patterns and guide improvements in paediatric oncology care.
Open AccessToronto Staging Guidelines for Wilms Tumour: The Meeting Point Between Clinicians and Epidemiologists—Results of the BENCHISTA-ITA Project
Background/Objectives: Despite overall excellent outcomes for Wilms tumour, regional variations in stage at diagnosis and care pathways remain a concern across Europe. We evaluated stage distribution, three-year survival, and treatment patterns in Italy, considering hospital care as a proxy for healthcare capacity and migration. Methods: Data were obtained from 26 population-based cancer registries (PBCRs), covering 148 patients (ages 0–14) diagnosed between 2013 and 2017, representing about 80% of the Italian population. Stage was classified according to the Toronto guidelines. Information on treatment and diagnosed/treating hospitals was collected. Stage at diagnosis was further refined using probabilistic linkage with the clinical registry 1.01 Model. Overall survival, defined as all-cause mortality, was estimated using the Kaplan–Meier method. Results: Most patients presented with localized disease (77%), 32% Stage I, while 19% were Stage IV. Three-year survival analysis showed significant differences between stages, ranging from 98% in patients with Stage I to 78% in the ones with Stage IV. No significant disparity across the Italian regions was observed in stage distribution or survival. Diagnoses and treatments were mostly (>90%) centralized in the same region for patients residing in the Centre or North of Italy. However, the cross-regional health migration from the South was of about 30% for diagnosis and larger for treatments. Conclusions: This study shows that standardized staging improves data comparability and highlights challenges in managing metastatic cases and regional care pathways. The results support the use of clinical and PBCR information to interpret survival patterns and guide improvements in paediatric oncology care.
- Open Access
Neuroblastoma by Stage at Diagnosis and Other Prognostic Factors: The Results of the BENCHISTA Italian Project—A Population-Based Study
Background: Neuroblastoma is the most common embryonal cancer. Since several population-based studies in Europe have revealed differences in 5-year survival across countries and regions. Objectives: We principally investigated the impact of stage at diagnosis on survival in Italy. Methods: Data were obtained from 26 population-based cancer registries (PBCRs), covering 319 cases (ages 0–14) diagnosed between 2013 and 2017, representing about 80% of the national population. Stage was classified according to the Toronto guidelines. Information on treatment and treating hospitals was also collected. Stage at diagnosis was further refined using probabilistic linkage with the Italian Neuroblastoma Registry (RINB). Results: Overall survival (OS), defined as all-cause mortality, was estimated using the Kaplan–Meier method. Most patients presented with stage M disease (37%), while a small proportion remained unclassified (2%). Three-year survival analysis showed significant differences between stages, ranging from >95% in localised (stage I) and MS stages to 78% in stage M (stage IV). No significant disparity across the Italian regions was observed in stage distribution or survival. Surgery and radiotherapy treatments of neuroblastoma were mostly centralized in the Centre and North of Italy. However, the cross-regional health migration from the South was limited to, and interpreted as appropriate for, high-volume centres. Conclusions: This population-based study highlights the high quality of care provided to children with neuroblastoma by an effective national clinical network. Compared with previous studies, we observed very limited variation across regions. A national childhood cancer registry remains essential to obtain a comprehensive picture of the country.
Open AccessNeuroblastoma by Stage at Diagnosis and Other Prognostic Factors: The Results of the BENCHISTA Italian Project—A Population-Based Study
Background: Neuroblastoma is the most common embryonal cancer. Since several population-based studies in Europe have revealed differences in 5-year survival across countries and regions. Objectives: We principally investigated the impact of stage at diagnosis on survival in Italy. Methods: Data were obtained from 26 population-based cancer registries (PBCRs), covering 319 cases (ages 0–14) diagnosed between 2013 and 2017, representing about 80% of the national population. Stage was classified according to the Toronto guidelines. Information on treatment and treating hospitals was also collected. Stage at diagnosis was further refined using probabilistic linkage with the Italian Neuroblastoma Registry (RINB). Results: Overall survival (OS), defined as all-cause mortality, was estimated using the Kaplan–Meier method. Most patients presented with stage M disease (37%), while a small proportion remained unclassified (2%). Three-year survival analysis showed significant differences between stages, ranging from >95% in localised (stage I) and MS stages to 78% in stage M (stage IV). No significant disparity across the Italian regions was observed in stage distribution or survival. Surgery and radiotherapy treatments of neuroblastoma were mostly centralized in the Centre and North of Italy. However, the cross-regional health migration from the South was limited to, and interpreted as appropriate for, high-volume centres. Conclusions: This population-based study highlights the high quality of care provided to children with neuroblastoma by an effective national clinical network. Compared with previous studies, we observed very limited variation across regions. A national childhood cancer registry remains essential to obtain a comprehensive picture of the country.
- Open Access
Improving the Connection Between Population-Based and National Clinical Pediatric Cancer Registries—A Pilot Study on Neuroblastoma: The Italian BENCHISTA-Ita Project
Background: Childhood cancers (CC) are rare and treatable; however, survival rates vary across Europe, with poorer outcomes in Eastern countries. Stage at diagnosis is one of the major prognostic factors. The BENCHISTA-Ita project aims to promote the use of the Toronto Guidelines by population-based cancer registries (PBCR) to standardize stage at diagnosis data collection. In Italy, regional cancer registries ensure data quality, while national clinical registries centralize pediatric cancer data. The aim of the study is to promote the linkage between PBCRs and national clinical registries to enhance data completeness. This study presents the results of linking BENCHISTA-Ita neuroblastoma cases with the Italian Neuroblastoma Registry (RINB) as a pilot study. Methods: The linkage process involved probabilistic matching using R software, considering variables such as sex, year of birth, and residence at diagnosis. The study included 294 neuroblastoma cases from BENCHISTA-Ita and 578 from RINB, diagnosed between 2013 and 2017. Results: Results showed that 272 of 294 BENCHISTA-Ita cases matched with RINB cases, improving the completeness of clinical variables such as stage at diagnosis, N-Myc amplification, and relapse/progression. The linkage increased the completeness of clinical variables in PBCR, such as stage at diagnosis from 81% to 99%, N-Myc from 47% to 86%, and relapse/progression from 68% to 98%. Additionally, the linkage improved RINB’s follow-up completeness from 59% to 97% and added new cases in both PBCR and RINB. Conclusions: This linkage demonstrates the potential to enrich both databases, improving data quality and harmonization of cancer indicators. The study highlights the importance of collaboration between PBCRs and clinical registries to ensure comprehensive data collection and enhance more informative population-based studies. Future efforts will focus on expanding the linkage to other national clinical registries.
Open AccessImproving the Connection Between Population-Based and National Clinical Pediatric Cancer Registries—A Pilot Study on Neuroblastoma: The Italian BENCHISTA-Ita Project
Background: Childhood cancers (CC) are rare and treatable; however, survival rates vary across Europe, with poorer outcomes in Eastern countries. Stage at diagnosis is one of the major prognostic factors. The BENCHISTA-Ita project aims to promote the use of the Toronto Guidelines by population-based cancer registries (PBCR) to standardize stage at diagnosis data collection. In Italy, regional cancer registries ensure data quality, while national clinical registries centralize pediatric cancer data. The aim of the study is to promote the linkage between PBCRs and national clinical registries to enhance data completeness. This study presents the results of linking BENCHISTA-Ita neuroblastoma cases with the Italian Neuroblastoma Registry (RINB) as a pilot study. Methods: The linkage process involved probabilistic matching using R software, considering variables such as sex, year of birth, and residence at diagnosis. The study included 294 neuroblastoma cases from BENCHISTA-Ita and 578 from RINB, diagnosed between 2013 and 2017. Results: Results showed that 272 of 294 BENCHISTA-Ita cases matched with RINB cases, improving the completeness of clinical variables such as stage at diagnosis, N-Myc amplification, and relapse/progression. The linkage increased the completeness of clinical variables in PBCR, such as stage at diagnosis from 81% to 99%, N-Myc from 47% to 86%, and relapse/progression from 68% to 98%. Additionally, the linkage improved RINB’s follow-up completeness from 59% to 97% and added new cases in both PBCR and RINB. Conclusions: This linkage demonstrates the potential to enrich both databases, improving data quality and harmonization of cancer indicators. The study highlights the importance of collaboration between PBCRs and clinical registries to ensure comprehensive data collection and enhance more informative population-based studies. Future efforts will focus on expanding the linkage to other national clinical registries.
- Open Access
- 10 April 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (4) , 222
Primary Central Nervous System Tumors in Adolescents: A Population-Based Study on Epidemiology and Clinical Pathways in a Challenging Age Group
Background: Oncological care of adolescent patients is often inconsistent, as they frequently fall between pediatric and adult services. The Childhood Cancer Registry of Campania (CCRC) is the Italian largest population-based registry specializing in children 0–19 years old, with a target population of approximately 1.1 million inhabitants. Material and Methods: This report presents epidemiological indicators and clinical pathways on primary brain tumors in adolescents (15–19 years) from the Campania region. Results: Over the study period (2008–2020), the cohort included 219 adolescents with newly diagnosed central nervous system (CNS) tumors with an annual average incidence rate (IR) of 48.9 cases per million/year. The 5-year observed survival rate after diagnosis of CNS tumor was 84.8%. Overall, the most common tumor site was the pituitary gland and craniopharyngeal duct, representing 22.4% of all tumors. The most frequently occurring malignant primary CNS tumor was germinoma, while the most common non-malignant tumor was pituitary adenoma. Most patients were referred to adult services and nearly half migrated outside the region to receive cancer care. Conclusions: Challenges in the care of adolescent oncology patients include limited access to specialized care, difficulties in transitioning from pediatric to adult institutions, distinct tumor biology, and the underrepresentation of adolescents in clinical trials. The care of adolescents with CNS tumors is fragmented across institutions and significant variations in practice exist between adult and pediatric practitioners.
- 10 April 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (4) , 222
Open AccessPrimary Central Nervous System Tumors in Adolescents: A Population-Based Study on Epidemiology and Clinical Pathways in a Challenging Age Group
Background: Oncological care of adolescent patients is often inconsistent, as they frequently fall between pediatric and adult services. The Childhood Cancer Registry of Campania (CCRC) is the Italian largest population-based registry specializing in children 0–19 years old, with a target population of approximately 1.1 million inhabitants. Material and Methods: This report presents epidemiological indicators and clinical pathways on primary brain tumors in adolescents (15–19 years) from the Campania region. Results: Over the study period (2008–2020), the cohort included 219 adolescents with newly diagnosed central nervous system (CNS) tumors with an annual average incidence rate (IR) of 48.9 cases per million/year. The 5-year observed survival rate after diagnosis of CNS tumor was 84.8%. Overall, the most common tumor site was the pituitary gland and craniopharyngeal duct, representing 22.4% of all tumors. The most frequently occurring malignant primary CNS tumor was germinoma, while the most common non-malignant tumor was pituitary adenoma. Most patients were referred to adult services and nearly half migrated outside the region to receive cancer care. Conclusions: Challenges in the care of adolescent oncology patients include limited access to specialized care, difficulties in transitioning from pediatric to adult institutions, distinct tumor biology, and the underrepresentation of adolescents in clinical trials. The care of adolescents with CNS tumors is fragmented across institutions and significant variations in practice exist between adult and pediatric practitioners.
- 23 May 2012
- Published by Baskent University in Experimental and Clinical Transplantation
- Vol. 10 (3) , 209-218
Current Concepts in Histocompatibility During Heart Transplant
Sensitized candidates for heart transplant usually end up on a long waiting list and have an increased risk of rejection, graft loss, and incidence of cardiac allograft vasculopathy. An increasing number of studies have demonstrated the negative effect of preformed and posttransplant antibodies on graft survival. Thus, in sensitized patients, the combination of new, appropriate, desensitization protocols, and monitoring of posttransplant development of donor-specific antibodies may improve short-term and long-term outcomes. Introduction of more-sensitive and more-specific techniques for antibody detection provides a valid tool for assessing the degree of pretransplant HLA histocompatibility, and, therefore, predicting the results of crossmatch in sensitized patients, which are difficult to transplant. Currently, there are no accurate and standard methods to determine the functional characteristics of antibodies detected by solid-phase assay and, therefore, to predict their clinical relevance. Therefore, the future of heart transplantation requires a better understanding of tissue typing techniques and the effect of anti-HLA antibodies on clinical outcome to prevent discrimination against sensitized patients at the time of organ allocation.
- 23 May 2012
- Published by Baskent University in Experimental and Clinical Transplantation
- Vol. 10 (3) , 209-218
Current Concepts in Histocompatibility During Heart Transplant
Sensitized candidates for heart transplant usually end up on a long waiting list and have an increased risk of rejection, graft loss, and incidence of cardiac allograft vasculopathy. An increasing number of studies have demonstrated the negative effect of preformed and posttransplant antibodies on graft survival. Thus, in sensitized patients, the combination of new, appropriate, desensitization protocols, and monitoring of posttransplant development of donor-specific antibodies may improve short-term and long-term outcomes. Introduction of more-sensitive and more-specific techniques for antibody detection provides a valid tool for assessing the degree of pretransplant HLA histocompatibility, and, therefore, predicting the results of crossmatch in sensitized patients, which are difficult to transplant. Currently, there are no accurate and standard methods to determine the functional characteristics of antibodies detected by solid-phase assay and, therefore, to predict their clinical relevance. Therefore, the future of heart transplantation requires a better understanding of tissue typing techniques and the effect of anti-HLA antibodies on clinical outcome to prevent discrimination against sensitized patients at the time of organ allocation.
- 13 February 2012
- Published by Wiley in Journal of Cellular Physiology
- Vol. 227 (11) , 3639-3647
Glycoxydation promotes vascular damage Via MAPK‐ERK/JNK pathways
Oxidation and glycation enhance foam cell formation via MAPK/JNK in euglycemic and diabetic subjects. Here, we investigated the effects of glycated and oxidized LDL (glc‐oxLDL) on MAPK‐ERK and JNK signaling pathways using human coronary smooth muscle cells. Glc‐oxLDL induced a broad cascade of MAPK/JNK‐dependent signaling transduction pathways and the AP‐1 complex. In glc‐oxLDL treated coronary arterioles, tumor necrosis factor (TNF) α increased JNK phosphorylation, whereas protein kinase inhibitor dimethylaminopurine (DMAP) prevented the TNF‐induced increase in JNK phosphorylation. The role of MKK4 and JNK were then investigated in vivo, using apolipoprotein E knockout (ApoE−/−) mice. Peritoneal macrophages, isolated from spontaneously hyperlipidemic but euglycemic mice showed increases in both proteins and phosphorylated proteins. Compared to streptozotocin‐treated diabetic C57BL6 and nondiabetic C57BL6 Wt mice, in streptozotocin‐diabetic ApoE−/− mice, the increment of foam cell formation corresponded to an increment of phosphorylation of JNK1, JNK2, and MMK4. Thus, we provide a first line of evidence that MAPK‐ERK/JNK pathways are involved in vascular damage induced by glycoxidation. J. Cell. Physiol. 227: 3639–3647, 2012.
- 13 February 2012
- Published by Wiley in Journal of Cellular Physiology
- Vol. 227 (11) , 3639-3647
Glycoxydation promotes vascular damage Via MAPK‐ERK/JNK pathways
Oxidation and glycation enhance foam cell formation via MAPK/JNK in euglycemic and diabetic subjects. Here, we investigated the effects of glycated and oxidized LDL (glc‐oxLDL) on MAPK‐ERK and JNK signaling pathways using human coronary smooth muscle cells. Glc‐oxLDL induced a broad cascade of MAPK/JNK‐dependent signaling transduction pathways and the AP‐1 complex. In glc‐oxLDL treated coronary arterioles, tumor necrosis factor (TNF) α increased JNK phosphorylation, whereas protein kinase inhibitor dimethylaminopurine (DMAP) prevented the TNF‐induced increase in JNK phosphorylation. The role of MKK4 and JNK were then investigated in vivo, using apolipoprotein E knockout (ApoE−/−) mice. Peritoneal macrophages, isolated from spontaneously hyperlipidemic but euglycemic mice showed increases in both proteins and phosphorylated proteins. Compared to streptozotocin‐treated diabetic C57BL6 and nondiabetic C57BL6 Wt mice, in streptozotocin‐diabetic ApoE−/− mice, the increment of foam cell formation corresponded to an increment of phosphorylation of JNK1, JNK2, and MMK4. Thus, we provide a first line of evidence that MAPK‐ERK/JNK pathways are involved in vascular damage induced by glycoxidation. J. Cell. Physiol. 227: 3639–3647, 2012.
- 1 November 2009
- Published by Elsevier in Fertility and Sterility
- Vol. 92 (5) , 1532-1535
CYP17 and CYP19 gene polymorphisms in women affected with endometriosis
- 1 November 2009
- Published by Elsevier in Fertility and Sterility
- Vol. 92 (5) , 1532-1535
CYP17 and CYP19 gene polymorphisms in women affected with endometriosis
- 15 September 2006
- Published by Springer Nature in Intensive Care Medicine
- Vol. 32 (11) , 1881-1888
Hyperbaric oxygen therapy prevents coagulation disorders in an experimental model of multiple organ failure syndrome
To evaluate the effects of hyperbaric oxygen (HBO) therapy on the coagulation cascade using an experimental model of multiple organ failure syndrome (MOFS).
- 15 September 2006
- Published by Springer Nature in Intensive Care Medicine
- Vol. 32 (11) , 1881-1888
Hyperbaric oxygen therapy prevents coagulation disorders in an experimental model of multiple organ failure syndrome
To evaluate the effects of hyperbaric oxygen (HBO) therapy on the coagulation cascade using an experimental model of multiple organ failure syndrome (MOFS).
- 1 January 2006
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 19 (12) , 1413-1420
Serum Osteocalcin and Parathyroid Hormone in Healthy Children Assessed with Two New Automated Assays
The recent introduction of new automated assays needs careful definition of reference values in healthy children. The aim of this study was to determine serum parathyroid hormone (PTH) and osteocalcin in a large group of healthy children according to age. We selected 2,288 healthy children (1,079 girls, 1,209 boys), aged 2-16 years. Serum PTH and osteocalcin were assayed with a two-site immunochemiluminometric assay adapted on an automated analyzer, the Liaison. Significant differences were found between the mean serum values of PTH and osteocalcin in boys and girls in all age groups (p <0.001). Boys' and girls' PTH values ranged from 3.42-22.30 ng/l and 2.31-24.49 ng/l, respectively; serum osteocalcin ranged from 3.85-17.80 nmol/l in boys and 3.74-17.38 nmol/l in girls. The results of this study contribute to the establishment of reference values in healthy children for PTH and osteocalcin assays.
- 1 January 2006
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 19 (12) , 1413-1420
Serum Osteocalcin and Parathyroid Hormone in Healthy Children Assessed with Two New Automated Assays
The recent introduction of new automated assays needs careful definition of reference values in healthy children. The aim of this study was to determine serum parathyroid hormone (PTH) and osteocalcin in a large group of healthy children according to age. We selected 2,288 healthy children (1,079 girls, 1,209 boys), aged 2-16 years. Serum PTH and osteocalcin were assayed with a two-site immunochemiluminometric assay adapted on an automated analyzer, the Liaison. Significant differences were found between the mean serum values of PTH and osteocalcin in boys and girls in all age groups (p <0.001). Boys' and girls' PTH values ranged from 3.42-22.30 ng/l and 2.31-24.49 ng/l, respectively; serum osteocalcin ranged from 3.85-17.80 nmol/l in boys and 3.74-17.38 nmol/l in girls. The results of this study contribute to the establishment of reference values in healthy children for PTH and osteocalcin assays.